Abivax skyrockets on positive Phase III results for obefazimod

Shares of French clinical-stage biotech Abivax (Euronext Paris: ABVX) were up an astonishing 389% at 43.55 euros in early trading, after, late yesterday, it announced positive top-line results from its Phase III ABTECT-1 (Study 105) and ABTECT-2 (Study 106) 8-week induction trials evaluating its oral, first-in-class miR-124 enhancer, obefazimod (ABX464), in adult patients with moderately to severely active ulcerative colitis (UC).

Abivax’ chief executive Marc de Garidel commented: “Today marks a significant milestone for Abivax, and more importantly, for the ulcerative colitis community. The strength of these results reinforces our belief in obefazimod, our first-in-class miR-124 enhancer, and its potential to become a transformative new treatment modality for patients with UC. Pending successful results from the 44-week maintenance trial, we are preparing to submit a new drug application to the FDA in the second half of 2026. We would like to thank the patients who participated in the trials as well as the investigators and staff at over 600 sites in 36 countries who contributed to the landmark trials.”